Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1982;22(4):359-65.
doi: 10.1007/BF00548406.

Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults

Comparative Study

Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults

S M Huang et al. Eur J Clin Pharmacol. 1982.

Abstract

Plasma and urinary levels of chlorpheniramine (CPM) and its 2 demethylated metabolites were measured by HPLC after i.v. and oral dosing. In 5 mg (maleate) i.v. bolus studies in 2 subjects, plasma CPM levels were fitted to triexponential equations with terminal half-lives (t 1/1) of 23 and 22 h and area of 3.6 and 3.21/kg, respectively. Intravenous data predicted hepatic blood extraction ratios for the 2 subjects to be 0.06 and 0,07, respectively. Absolute bioavailability from oral solution (10 mg) was 59 and 34%, and from tablets (8 mg) 44 and 25%, respectively, indicating extensive gut first-pass metabolism. Mean t 1/2 from 7 oral fasting studies in 5 subjects was 28 h (19-43 h). Mean absorption lag time was 0.7 h (0.4-1.3 h), and mean peak time was 2.8 h (2-4 h). In 2 subjects, 6 mg solutions were given every 12 h for 9 doses; good correlation between single and multiple dose kinetics was found. Significant accumulation was demonstrated in simulation studies with frequent daily dosing. Estimated accumulation ratios vary from 4.1 to 9.4 (mean 6.5). The t 1/2 from urinary data (collected for 12 days) was consistent with plasma data. The above results suggest the need to reexamine the current practice of frequent daily dosing and the use of sustained or controlled release dosage forms of this drug. The possible cause of reduced plasma clearance of CPM in renal patients is discussed.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Pharmacokinet Biopharm. 1975 Feb;3(1):1-11 - PubMed
    1. J Pharmacokinet Biopharm. 1978 Dec;6(6):539-46 - PubMed
    1. J Pharm Sci. 1979 Dec;68(12):1546-7 - PubMed
    1. J Allergy Clin Immunol. 1973 Feb;51(2):71-7 - PubMed
    1. Anal Chem. 1977 Jun;49(7):1085-6 - PubMed

Publication types

Substances

LinkOut - more resources